Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
Saye Khoo(University of Liverpool), Ján Dixon(University of Sheffield), Nichola Downs(University Hospital Southampton NHS Foundation Trust), Ana I. Cubas-Atienzar, Lara Lavelle-Langham(University of Liverpool), Sean Ewings(Cancer Research UK), Shazaad Ahmad(Manchester University NHS Foundation Trust), Fred Hayden, Julian A. Hiscox(University of Liverpool), Amanda Buadi(University Hospital Southampton NHS Foundation Trust), Amy Lucas, Rachel Byrne(Kessler Foundation), Wayne Holman, Anna V. Song(Lancashire Teaching Hospitals NHS Foundation Trust), David Cameron(Lancashire Teaching Hospitals NHS Foundation Trust), Richard J. Fitzgerald(University of Limerick), Josh Northey(University Hospital Southampton NHS Foundation Trust), Jayne Jones, Thomas Jaki(MRC Biostatistics Unit), Victoria Shaw(University of Liverpool), Thomas Edwards(Liverpool School of Tropical Medicine), Nicholas I. Paton(St George's Hospital), I’ah Donovan-Banfield(University of Liverpool), Helen Reynolds(University of Liverpool), David G. Lalloo(Liverpool School of Tropical Medicine), Michael Jacobs(Roland Hill (United Kingdom)), Emma Knox(University of Southampton), Richard J. Knight(Methodist Hospital), Pavel Mozgunov(University of Cambridge), Wendy Painter, Jimstan Periselneris(King's College Hospital NHS Foundation Trust), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Lauren Walker(University of Liverpool), Katie Bullock(University of Liverpool), Gareth Griffiths(NIHR Evaluation Trials and Studies Coordinating Centre), Christie Woods(Royal Liverpool and Broadgreen University Hospital NHS Trust), Michelle Tetlow(University of Liverpool), Ulrika Lorch, Andrew N. Freedman, Colin Hale(Royal Liverpool and Broadgreen University Hospital NHS Trust), Rebecca Lyon(Royal Liverpool and Broadgreen University Hospital NHS Trust), Geoffrey Saunders(University of Southampton), Janet Darbyshire(MRC Clinical Trials Unit at UCL), Justin Chiong(University of Liverpool), Calley Middleton(University of Southampton), Dennis Hadjiyiannakis(Lancashire Teaching Hospitals NHS Foundation Trust), William Greenhalf, Chris Williams(Royal Liverpool and Broadgreen University Hospital NHS Trust)
Cited by 81
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k